Sequencing the next generation of glioblastomas

References

• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803–820.
   PubMed Web of Science ®Google Scholar
• Wang H, Xu T, Jiang Y, et al. The challenges and the promise of molecular targeted therapy in malignant gliomas. Neoplasia. 2015;17:239–255.
   PubMed Web of Science ®Google Scholar
• Batich KA, Sampson JH. Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. Expert Opin Pharmacother. 2014;15:2047–2061.
   PubMed Web of Science ®Google Scholar
• Noroxe DS, Poulsen HS, Lassen U. Hallmarks of glioblastoma: a systematic review. ESMO Open. 2016;1:e000144.
   PubMed Web of Science ®Google Scholar
• Sullivan JP, Nahed BV, Madden MW, et al. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014;4:1299–1309.
   PubMed Web of Science ®Google Scholar
• Aldape K, Zadeh G, Mansouri S, et al. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129:829–848.
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64:6892–6899.
   PubMed Web of Science ®Google Scholar
• Olar A, Aldape KD. Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol. 2014;232:165–177.
   PubMed Web of Science ®Google Scholar
• Movassaghi M, Shabihkhani M, Hojat SA, et al. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats. Exp Mol Pathol. 2017;103:87–93.
   PubMed Web of Science ®Google Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507.
   PubMed Web of Science ®Google Scholar
• Li R, Li H, Yan W, et al. Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution. Oncotarget. 2015;6:7318–7324.
   PubMed Web of Science ®Google Scholar
• Friedmann-Morvinski D. Glioblastoma heterogeneity and cancer cell plasticity. Crit Rev Oncog. 2014;19:327–336.
   PubMedGoogle Scholar
• Parker NR, Hudson AL, Khong P, et al. Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Sci Rep. 2016;6:22477.
   PubMed Web of Science ®Google Scholar
• Mooney KL, Choy W, Sidhu S, et al. The role of CD44 in glioblastoma multiforme. J Clin Neurosci. 2016;34:1–5.
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110.
   PubMed Web of Science ®Google Scholar
• Bhat KPL, Balasubramaniyan V, Vaillant B, et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell. 2013;24:331–346.
   PubMed Web of Science ®Google Scholar
• Sandmann T, Bourgon R, Garcia J, et al. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio Trial. J Clin Oncol. 2015;33:2735–2744.
   PubMed Web of Science ®Google Scholar
• Colman H, Zhang L, Sulman EP, et al. A multigene predictor of outcome in glioblastoma. Neuro-oncology. 2010;12:49–57.
   PubMed Web of Science ®Google Scholar
• Lindsay KW, Bone I, Fuller G. Neurology and neurosurgery illustrated. Oxford UK: Elsevier Health Sciences UK; 2010:310–317.
   Google Scholar
• Zhong J, Paul A, Kellie SJ, et al. Mesenchymal migration as a therapeutic target in glioblastoma. J Oncol. 2010;2010:430142.
   PubMedGoogle Scholar
• Iser IC, Pereira MB, Lenz G, et al. The epithelial-to-mesenchymal transition-like process in glioblastoma: an updated systematic review and in silico investigation. Med Res Rev. 2017;37:271–313.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol. 2011;5:117–129.
   PubMedGoogle Scholar
• Redzic JS, Ung TH, Graner MW. Glioblastoma extracellular vesicles: reservoirs of potential biomarkers. Pharmgenomics Pers Med. 2014;7:65–77.
   PubMedGoogle Scholar
• Zacher A, Kaulich K, Stepanow S, et al. Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel. Brain Pathol. 2017;27:146–159.
   PubMed Web of Science ®Google Scholar
• Engler JR, Robinson AE, Smirnov I, et al. Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS One. 2012;7:e43339.
   PubMed Web of Science ®Google Scholar
• Song YC, Lu GX, Zhang HW, et al. Proteogenomic characterization and integrative analysis of glioblastoma multiforme. Oncotarget. 2017;8:97304–97312.
   PubMedGoogle Scholar
• Rick J, Chandra A, Aghi MK. Tumor treating fields: a new approach to glioblastoma therapy. J Neurooncol 2018 [cited Jan 18]. DOI: 10.1007/s11060-018-2768-x. [Epub ahead of print].
   PubMedGoogle Scholar
• Rulseh AM, Keller J, Klener J, et al. Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields. World J Surg Oncol. 2012;10:220.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma. A randomized clinical trial. JAMA. 2017;318:2306–2316.
   PubMed Web of Science ®Google Scholar
• Arnone GD, Bhimani AD, Aguilar T, et al. Localized targeted antiangiogenic drug delivery for glioblastoma. J Neurooncol. 2018;137:223–231.
   PubMed Web of Science ®Google Scholar
• Paolillo M, Boselli C, Schinelli S. Glioblastoma under siege: an overview of current therapeutic strategies. Brain Sci. 2018;8:E15.
   PubMed Web of Science ®Google Scholar
• Sims JS, Ung TH, Neira JA, et al. Biomarkers for glioma immunotherapy: the next generation. J Neurooncol. 2015;123:359–372.
   PubMed Web of Science ®Google Scholar
• Lieberman NAP, Vitanza NA, Crane CA. Immunotherapy for brain tumors: understanding early successes and limitations. Expert Rev Neurother. 2018;18:251–259.
   PubMed Web of Science ®Google Scholar
• Finocchiaro G, Pellegatta S. Perspectives for immunotherapy in glioblastoma treatment. Curr Opin Oncol. 2014;26:608–614.
   PubMed Web of Science ®Google Scholar
• Artene SA, Tuta C, Dragoi A, et al. Current and emerging EGFR therapies for glioblastoma. J Immunoassay Immunochem. 2018;39:1–11.
   PubMedGoogle Scholar
• Xu LW, Chow KK, Lim M, et al. Current vaccine trials in glioblastoma: a review. J Immunol Res. 2014;2014:796856.
   PubMed Web of Science ®Google Scholar
• Lemee JM, Clavreul A, Menei P. Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone. Neuro Oncol. 2015;17:1322–1332.
   PubMed Web of Science ®Google Scholar
• van Lith SA, Navis AC, Lenting K, et al. Identification of a novel inactivating mutation in isocitrate dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma. Sci Rep. 2016;6:30486.
   PubMed Web of Science ®Google Scholar
• de Abreu FB, Peterson JD, Amos CI, et al. Effective quality management practices in routine clinical next-generation sequencing. Clin Chem Lab Med. 2016;54:761–771.
   PubMed Web of Science ®Google Scholar
• Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116:597–602.
   PubMed Web of Science ®Google Scholar
• Waitkus MS, Diplas BH, Yan H. Isocitrate dehydrogenase mutations in gliomas. Neuro-oncology. 2016;18:16–26.
   PubMed Web of Science ®Google Scholar
• Kurian KM, Haynes HR, Crosby C, et al. IDH mutation analysis in gliomas as a diagnostic and prognostic biomarker. Br J Neurosurg. 2013;27:442–445.
   PubMed Web of Science ®Google Scholar
• Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15:6002–6007.
   PubMed Web of Science ®Google Scholar
• Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-oncology. 2009;11:341–347.
   PubMed Web of Science ®Google Scholar
• Killela PJ, Pirozzi CJ, Healy P, et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget. 2014;5:1515–1525.
   PubMed Web of Science ®Google Scholar
• Thomas L, Di Stefano AL, Ducray F. Predictive biomarkers in adult gliomas: the present and the future. Curr Opin Oncol. 2013;25:689–694.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174:1149–1153.
   PubMed Web of Science ®Google Scholar
• Guo C, Pirozzi CJ, Lopez GY, et al. Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. Curr Opin Neurol. 2011;24:648–652.
   PubMed Web of Science ®Google Scholar
• Ballester LY, Fuller GN, Powell SZ, et al. Retrospective analysis of molecular and immunohistochemical characterization of 381 primary brain tumors. J Neuropathol Exp Neurol. 2017;76:179–188.
   PubMed Web of Science ®Google Scholar
• Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, et al. Advances in the molecular genetics of gliomas – implications for classification and therapy. Nat Rev Clin Oncol. 2017;14:434–452.
   PubMed Web of Science ®Google Scholar
• Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA. 2013;110:4009–4014.
   PubMed Web of Science ®Google Scholar
• Soeda A, Hara A, Kunisada T, et al. The evidence of glioblastoma heterogeneity. Sci Rep. 2015;5:7979.
   PubMed Web of Science ®Google Scholar
• Aum DJ, Kim DH, Beaumont TL, et al. Molecular and cellular heterogeneity: the hallmark of glioblastoma. Neurosurg Focus. 2014;37:E11.
   PubMed Web of Science ®Google Scholar
• Eder K, Kalman B. Molecular heterogeneity of glioblastoma and its clinical relevance. Pathol Oncol Res. 2014;20:777–787.
   PubMed Web of Science ®Google Scholar
• Meyer M, Reimand J, Lan X, et al. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci USA. 2015;112:851–856.
   PubMed Web of Science ®Google Scholar
• Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011;20:810–817.
   PubMed Web of Science ®Google Scholar
• Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344:1396–1401.
   PubMed Web of Science ®Google Scholar
• Kim H, Zheng S, Amini SS, et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015;25:316–327.
   PubMed Web of Science ®Google Scholar
• Liu Q, Liu Y, Li W, et al. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma. Acta Neuropathol. 2015;130:587–597.
   PubMed Web of Science ®Google Scholar
• Abou-El-Ardat K, Seifert M, Becker K, et al. Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas. Neuro Oncol. 2017;19:546–557.
   PubMed Web of Science ®Google Scholar
• Lee JK, Wang J, Sa JK, et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat Genet. 2017;49:594–599.
   PubMed Web of Science ®Google Scholar
• Zheng S, Fu J, Vegesna R, et al. A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. Genes Dev. 2013;27:1462–1472.
   PubMed Web of Science ®Google Scholar
• Szerlip NJ, Pedraza A, Chakravarty D, et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci USA. 2012;109:3041–3046.
   PubMed Web of Science ®Google Scholar
• Kumar A, Boyle EA, Tokita M, et al. Deep sequencing of multiple regions of glial tumors reveals spatial heterogeneity for mutations in clinically relevant genes. Genome Biol. 2014;15:530.
   PubMed Web of Science ®Google Scholar
• Furgason JM, Koncar RF, Michelhaugh SK, et al. Whole genome sequence analysis links chromothripsis to EGFR, MDM2, MDM4, and CDK4 amplification in glioblastoma. Oncoscience. 2015;2:618–628.
   PubMedGoogle Scholar
• Aubry M, de Tayrac M, Etcheverry A, et al. From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity. Oncotarget. 2015;6:12094–12109.
   PubMedGoogle Scholar
• Venteicher AS, Tirosh I, Hebert C, et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science. 2017;355:eaai8478.
   PubMed Web of Science ®Google Scholar
• Wang Q, Hu B, Hu X, et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 2017;32:42–56.e6.
   PubMed Web of Science ®Google Scholar
• Muller S, Liu SJ, Di Lullo E, et al. Single-cell sequencing maps gene expression to mutational phylogenies in PDGF- and EGF-driven gliomas. Mol Syst Biol. 2016;12:889.
   PubMed Web of Science ®Google Scholar
• Francis JM, Zhang CZ, Maire CL, et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 2014;4:956–971.
   PubMed Web of Science ®Google Scholar
• Nathanson DA, Gini B, Mottahedeh J, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014;343:72–76.
   PubMed Web of Science ®Google Scholar
• Choi S, Yu Y, Grimmer MR, et al. Temozolomide-associated hypermutation in gliomas. Neuro Oncol. 2018. DOI: 10.1093/neuonc/noy016. [Epub ahead of print].
   Google Scholar
• Kim J, Lee IH, Cho HJ, et al. Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell. 2015;28:318–328.
   PubMed Web of Science ®Google Scholar
• van Thuijl HF, Mazor T, Johnson BE, et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol. 2015;129:597–607.
   PubMed Web of Science ®Google Scholar
• Muscat AM, Wong NC, Drummond KJ, et al. The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection. Oncotarget. 2018;9:7844–7858.
   PubMedGoogle Scholar
• Wang J, Cazzato E, Ladewig E, et al. Clonal evolution of glioblastoma under therapy. Nat Genet. 2016;48:768–776.
   PubMed Web of Science ®Google Scholar
• Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res. 2009;15:4622–4629.
   PubMed Web of Science ®Google Scholar
• von Neubeck C, Seidlitz A, Kitzler HH, et al. Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs. Br J Radiol. 2015;88:20150354.
   PubMed Web of Science ®Google Scholar
• Chiang GC, Kovanlikaya I, Choi C, et al. Magnetic resonance spectroscopy, positron emission tomography and radiogenomics-relevance to glioma. Front Neurol. 2018;9:33.
   PubMed Web of Science ®Google Scholar
• Chow D, Chang P, Weinberg BD, et al. Imaging genetic heterogeneity in glioblastoma and other glial tumors: review of current methods and future directions. Am J Roentgenol. 2018;210:30–38.
   PubMed Web of Science ®Google Scholar
• Demerath T, Simon-Gabriel CP, Kellner E, et al. Mesoscopic imaging of glioblastomas: Are diffusion, perfusion and spectroscopic measures influenced by the radiogenetic phenotype? Neuroradiol J. 2017;30:36–47.
   PubMed Web of Science ®Google Scholar
• Liu X, Mangla R, Tian W, et al. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma. J Neurooncol. 2017;135:553–560.
   PubMed Web of Science ®Google Scholar
• Hu LS, Ning S, Eschbacher JM, et al. Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. Neuro-Oncology. 2017;19:128–137.
   PubMed Web of Science ®Google Scholar
• Ellingson BM. Radiogenomics and imaging phenotypes in glioblastoma: novel observations and correlation with molecular characteristics. Curr Neurol Neurosci Rep. 2015;15:506.
   PubMed Web of Science ®Google Scholar
• Kickingereder P, Bonekamp D, Nowosielski M, et al. Radiogenomics of glioblastoma: Machine learning-based classification of molecular characteristics by using multiparametric and multiregional MR imaging features. Radiology. 2016;281:907–918.
   PubMed Web of Science ®Google Scholar
• Zinn PO, Mahajan B, Sathyan P, et al. Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS One. 2011;6:e25451.
   PubMed Web of Science ®Google Scholar
• Cui Y, Ren S, Tha KK, et al. Volume of high-risk intratumoral subregions at multi-parametric MR imaging predicts overall survival and complements molecular analysis of glioblastoma. Eur Radiol. 2017;27:3583–3592.
   PubMed Web of Science ®Google Scholar
• Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555:469–474.
   PubMed Web of Science ®Google Scholar
• Westphal M, Lamszus K. Circulating biomarkers for gliomas. Nat Rev Neurol. 2015;11:556–566.
   PubMed Web of Science ®Google Scholar
• Suva ML. Genetics and epigenetics of gliomas. Swiss Med Wkly. 2014;144:w14018.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.
   PubMed Web of Science ®Google Scholar
• Wick W, Weller M, van den Bent M, et al. MGMT testing-the challenges for biomarker-based glioma treatment. Nat Rev Neurol. 2014;10:372–385.
   PubMed Web of Science ®Google Scholar
• Mollemann M, Wolter M, Felsberg J, et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer. 2005;113:379–385.
   PubMed Web of Science ®Google Scholar
• Parkinson JF, Wheeler HR, Clarkson A, et al. Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol. 2008;87:71–78.
   PubMed Web of Science ®Google Scholar
• Lin AL, White M, Miller-Thomas MM, et al. Molecular and histologic characteristics of pseudoprogression in diffuse gliomas. J Neurooncol. 2016;130:529–533.
   PubMed Web of Science ®Google Scholar
• Kros JM, Mustafa DM, Dekker LJ, et al. Circulating glioma biomarkers. Neuro-oncology. 2015;17:343–360.
   PubMed Web of Science ®Google Scholar
• Qian X, Tan H, Zhang J, et al. Identification of biomarkers for pseudo and true progression of GBM based on radiogenomics study. Oncotarget. 2016;7:55377–55394.
   PubMedGoogle Scholar
• Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707–2714.
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715–2722.
   PubMed Web of Science ®Google Scholar
• Vogazianou AP, Chan R, Backlund LM, et al. Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. Neuro-oncology. 2010;12:664–678.
   PubMed Web of Science ®Google Scholar
• Hartmann C, Hentschel B, Simon M, et al. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res. 2013;19:5146–5157.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012;3:709–722.
   PubMed Web of Science ®Google Scholar
• Moorcraft SY, Gonzalez D, Walker BA. Understanding next generation sequencing in oncology: a guide for oncologists. Crit Rev Oncol Hematol. 2015;96:463–474.
   PubMed Web of Science ®Google Scholar
• Nagarajan RP, Costello JF. Epigenetic mechanisms in glioblastoma multiforme. Semin Cancer Biol. 2009;19:188–197.
   PubMed Web of Science ®Google Scholar
• Santangelo A, Tamanini A, Cabrini G, et al. Circulating microRNAs as emerging non-invasive biomarkers for gliomas. Ann Transl Med. 2017;5:277.
   PubMed Web of Science ®Google Scholar
• Majchrzak-Celinska A, Paluszczak J, Szalata M, et al. The methylation of a panel of genes differentiates low-grade from high-grade gliomas. Tumour Biol. 2015;36:3831–3841.
   PubMedGoogle Scholar
• Kondo Y, Katsushima K, Ohka F, et al. Epigenetic dysregulation in glioma. Cancer Sci. 2014;105:363–369.
   PubMed Web of Science ®Google Scholar
• Tumilson CA, Lea RW, Alder JE, et al. Circulating microRNA biomarkers for glioma and predicting response to therapy. Mol Neurobiol. 2014;50:545–558.
   PubMed Web of Science ®Google Scholar
• Clarke J, Penas C, Pastori C, et al. Epigenetic pathways and glioblastoma treatment. Epigenetics. 2013;8:785–795.
   PubMed Web of Science ®Google Scholar
• Kim E, Kim M, Woo DH, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013;23:839–852.
   PubMed Web of Science ®Google Scholar
• Kalluri R. The biology and function of exosomes in cancer. J Clin Invest. 2016;126:1208–1215.
   PubMed Web of Science ®Google Scholar
• Mallawaaratchy DM, Hallal S, Russell B, et al. Comprehensive proteome profiling of glioblastoma-derived extracellular vesicles identifies markers for more aggressive disease. J Neurooncol. 2017;131:233–244.
   PubMed Web of Science ®Google Scholar
• Ruivo CF, Adem B, Silva M, et al. The biology of cancer exosomes: insights and new perspectives. Cancer Res. 2017;77:6480–6488.
   PubMed Web of Science ®Google Scholar
• Zappulli V, Friis KP, Fitzpatrick Z, et al. Extracellular vesicles and intercellular communication within the nervous system. J Clin Invest. 2016;126:1198–1207.
   PubMed Web of Science ®Google Scholar
• Andre-Gregoire G, Gavard J. Spitting out the demons: extracellular vesicles in glioblastoma. Cell Adh Migr. 2017;11:164–172.
   PubMed Web of Science ®Google Scholar
• Li CC, Eaton SA, Young PE, et al. Glioma microvesicles carry selectively packaged coding and non-coding RNAs which alter gene expression in recipient cells. RNA Biol. 2013;10:1333–1344.
   PubMed Web of Science ®Google Scholar
• Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200:373–383.
   PubMed Web of Science ®Google Scholar
• Rufino-Ramos D, Albuquerque PR, Carmona V, et al. Extracellular vesicles: novel promising delivery systems for therapy of brain diseases. J Control Release. 2017;262:247–258.
   PubMed Web of Science ®Google Scholar
• Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470–1476.
   PubMed Web of Science ®Google Scholar
• Noerholm M, Balaj L, Limperg T, et al. RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer. 2012;12:22.
   PubMed Web of Science ®Google Scholar
• Street JM, Barran PE, Mackay CL, et al. Identification and proteomic profiling of exosomes in human cerebrospinal fluid. J Transl Med. 2012;10:5.
   PubMed Web of Science ®Google Scholar
• Horak P, Frohling S, Glimm H. Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open. 2016;1:e000094.
   PubMed Web of Science ®Google Scholar
• Serrati S, De Summa S, Pilato B, et al. Next-generation sequencing: advances and applications in cancer diagnosis. Oncotargets Ther. 2016;9:7355–7365.
   PubMed Web of Science ®Google Scholar
• LeBlanc VG, Marra MA. Next-generation sequencing approaches in cancer: where have they brought us and where will they take us? Cancers (Basel). 2015;7:1925–1958.
   PubMed Web of Science ®Google Scholar
• Lang MF, Yang S, Zhao C, et al. Genome-wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. PLoS One. 2012;7:e36248.
   PubMed Web of Science ®Google Scholar
• Hua D, Mo F, Ding D, et al. A catalogue of glioblastoma and brain MicroRNAs identified by deep sequencing. Omics. 2012;16:690–699.
   PubMed Web of Science ®Google Scholar
• Lin B, Madan A, Yoon JG, et al. Massively parallel signature sequencing and bioinformatics analysis identifies up-regulation of TGFBI and SOX4 in human glioblastoma. PLoS One. 2010;5:e10210.
   PubMed Web of Science ®Google Scholar
• Zhang W, Liu Y, Hu H, et al. ALDH1A3: a marker of mesenchymal phenotype in gliomas associated with cell invasion. PLoS One. 2015;10:e0142856.
   PubMed Web of Science ®Google Scholar
• Cimino PJ, Bredemeyer A, Abel HJ, et al. A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel. Exp Mol Pathol. 2015;98:568–573.
   PubMed Web of Science ®Google Scholar
• Virk SM, Gibson RM, Quinones-Mateu ME, et al. Identification of variants in primary and recurrent glioblastoma using a cancer-specific gene panel and whole exome sequencing. PLoS One. 2015;10:e0124178.
   PubMed Web of Science ®Google Scholar
• Johnson A, Severson E, Gay L, et al. Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Oncologist. 2017;22:1478–1490.
   PubMed Web of Science ®Google Scholar
• Postel M, Roosen A, Laurent-Puig P, et al. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. Expert Rev Mol Diagn. 2018;18:7–17.
   PubMed Web of Science ®Google Scholar
• Figueroa JM, Carter BS. Detection of glioblastoma in biofluids. J Neurosurg. 2017. DOI: 10.3171/2017.3.JNS162280. [Epub ahead of print].
   PubMedGoogle Scholar
• Schwaederle M, Husain H, Fanta PT, et al. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. 2016;7:9707–9717.
   PubMed Web of Science ®Google Scholar
• Touat M, Duran-Pena A, Alentorn A, et al. Emerging circulating biomarkers in glioblastoma: promises and challenges. Exp Rev Mol Diagn. 2015;15:1311–1323.
   PubMed Web of Science ®Google Scholar
• Mullauer L. Next generation sequencing: clinical applications in solid tumours. Memo. 2017;10:244–247.
   PubMedGoogle Scholar
• Pan W, Gu W, Nagpal S, et al. Brain tumor mutations detected in cerebral spinal fluid. Clin Chem. 2015;61:514–522.
   PubMed Web of Science ®Google Scholar
• Nagahashi M, Shimada Y, Ichikawa H, et al. Formalin-fixed paraffin-embedded sample conditions for deep next generation sequencing. J Surg Res. 2017;220:125–132.
   PubMed Web of Science ®Google Scholar
• Esteve-Codina A, Arpi O, Martinez-Garcia M, et al. A comparison of RNA-Seq results from paired formalin-fixed paraffin-embedded and fresh-frozen glioblastoma tissue samples. PLoS One. 2017;12:e0170632.
   PubMed Web of Science ®Google Scholar
• Sahm F, Schrimpf D, Jones DT, et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 2016;131:903–910.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Burger P, et al. International Society of Neuropathology–Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014;24:429–435.
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Wald AI, Melan MA, et al. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro Oncol. 2016;18:379–387.
   PubMed Web of Science ®Google Scholar
• Gullapalli RR, Desai KV, Santana-Santos L, et al. Next generation sequencing in clinical medicine: challenges and lessons for pathology and biomedical informatics. J Pathol Inform. 2012;3:40.
   PubMedGoogle Scholar
• Rizzo JM, Buck MJ. Key principles and clinical applications of “next-generation” DNA sequencing. Cancer Prev Res (Phila). 2012;5:887–900.
   PubMed Web of Science ®Google Scholar
• Lih CJ, Takebe N. Considerations of developing an NGS assay for clinical applications in precision oncology: the NCI-MATCH NGS assay experience. Curr Probl Cancer. 2017;41:201–211.
   PubMed Web of Science ®Google Scholar